Agios Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Agios Pharmaceuticals received FDA approval for AQVESME in thalassemia and a positive EU opinion for PYRUKYND in thalassemia, while reporting a return to net loss and mixed results from its sickle cell disease trial.
NASDAQ
Agios Pharmaceuticals achieved net income in 2024 due to the sale of oncology royalty rights and a milestone payment, while advancing its rare disease pipeline, particularly PYRUKYND.
NASDAQ
Agios Pharmaceuticals reports its full year 2023 financial results, highlighting progress in its rare disease pipeline and commercialization of PYRUKYND.